Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

In the United States, both ibrutinib, a Bruton’s tyrosine kinase inhibitor, and venetoclax, a B-cell lymphoma 2 inhibitor, are approved for the treatment of chronic lymphocytic leukemia (CLL) in the frontline and relapsed/refractory settings. Preclinical evidence of synergistic antitumor activity with ibrutinib + venetoclax combination therapy demonstrated high rates of remission with undetectable minimal residual disease (uMRD) in patients with CLL or mantle-cell lymphoma. The multicenter phase 2 CAPTIVATE study (PCYC-1142; NCT02910583) is evaluating ibrutinib + venetoclax combination therapy in the first-line treatment of CLL/small lymphocytic lymphoma.

In the CAPTIVATE study, eligible patients were aged <70 years and were previously untreated for CLL requiring therapy. Patients received ibrutinib 420 mg daily for 3 cycles, followed by ibrutinib + venetoclax (5-week ramp-up to 400 mg daily orally) for 12 cycles. MRD-guided randomization occurred at 24 cycles, where patients were assessed for bone marrow (BM) uMRD; only MRD-positive patients were permitted to continue ibrutinib. The key end points prior to MRD-guided randomization included uMRD (<10-4 by 8-color flow cytometry), venetoclax-related tumor lysis syndrome (TLS) risk, pharmacokinetics, and adverse events (AEs). MRD status was evaluated in peripheral blood (PB) after 6, 9, and 12 cycles of ibrutinib + venetoclax, and in BM after 12 cycles of ibrutinib + venetoclax. A total of 164 patients were enrolled in the study, and 151 patients (90%) completed all 12 cycles of ibrutinib + venetoclax. The median age in the study population was 58 years; 20% had del(17p) or TP53 mutation, 17% had del(11q) alteration without del(17p), 19% had complex karyotype, 59% had unmutated IGHV, and 32% had lymph nodes ≥5 cm. The median duration of treatment was 14.7 months with ibrutinib and 12.0 months with venetoclax.

At any time after baseline, uMRD was achieved in 75% of patients (122/163) in PB and in 72% of patients (111/155) in BM; 93% of patients with uMRD in PB with matched BM samples achieved uMRD in both PB and BM. The proportion of patients who achieved PB uMRD following combined ibrutinib + venetoclax increased over time (after 6 cycles, 57%; after 9 cycles, 68%; after 12 cycles, 73%). The uMRD achieved in BM extended to all high-risk subgroups, including the del(17p) or TP53 mutation, del(11q), trisomy 12, and unmutated-IGHV status groups. Rates of uMRD in PB were also consistent with BM results.

At a median follow-up of 14.7 months (range, 0.5-19.9), response by International Workshop on Chronic Lymphocytic Leukemia criteria was achieved in 97% of patients, 3 patients (2%) had disease progression (1 Richter transformation during single-agent ibrutinib lead-in, 1 after discontinuation of ibrutinib lead-in due to AE, and 1 during treatment with ibrutinib + venetoclax).

After 3 cycles of ibrutinib lead-in, hospitalization was avoided in 76% of at-risk patients, and TLS risk was downgraded from high baseline risk to medium or low risk.

The most common AEs (any grade, in ≥15% of patients) during both single-agent ibrutinib and ibrutinib + venetoclax treatment were diarrhea, arthralgia, fatigue, headache, nausea, upper respiratory tract infection, neutropenia, vomiting, hypertension, and thrombocytopenia. AEs leading to treatment discontinuation occurred in 5% of patients treated with ibrutinib + venetoclax). Overall, the most common grade 3/4 AEs included neutropenia (35%), hypertension (7%), thrombocytopenia (5%), and diarrhea (5%).

Based on these results, it was concluded that first-line ibrutinib + venetoclax treatment resulted in high rates of uMRD in both PB and BM in patients with CLL, with a safety profile consistent with AEs known for both agents.

Tam CS, et al. ASH Abstract 35. Session 642.

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: